Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 06 June, 2013 and appeared in  DietObesityIssue 680

Artificial Sweeteners May Affect Blood Glucose Levels and Insulin Response

Sucralose, the artificial sweetener of Splenda®, was found to have an effect on the absorption of glucose and subsequent insulin secretion in non-diabetic, obese individuals....

Advertisement

M. Yanina Pepino, PhD, and colleagues out of Washington University School of Medicine, St. Louis, began looking at non-nutritive sweeteners such as Splenda® (sucralose) and the metabolic response following its ingestion. Previous studies have indicated metabolic effects in animal models but the actual effects of these sweeteners in people still remain uncertain.

Generally, artificial sweeteners were thought to have no effect on our metabolism nor increase the calorie intake making them a perfect substitute for sugar in diet products. Added in small amounts to our food, these artificial sweeteners interact with receptors on the tongue to provide that same sweet sensation as sugar. However, it has been noted that in animals, these artificial sweeteners bind to similar receptors in the mouth as those found along the GI tract and in the pancreas leading to insulin release and glucose absorption.

To better understand the potential effects of non-nutritive sweeteners in humans, Pepino's research group studied the effects on hormones and glucose of sucralose use in 17 morbidly obese, insulin sensitive individuals who have no prior use of the food additive. Using a randomized crossover design, researchers conducted a 5-hour modified oral glucose tolerance test upon two separate occasions. Patients either consumed sucralose or water 10 minutes prior to the first glucose administration. Prior to the second glucose administration, each patient drank the opposite of what they had in the first test.

In consideration of the study population, Pepino said, "Most of the studies of artificial sweeteners have been conducted in healthy, lean individuals…We wanted to study this population because these sweeteners frequently are recommended to them as a way to make their diets healthier by limiting calorie intake."

The authors reported a greater effect on the body's hormones and glucose regulation with the ingestion of sucralose compared to water. They also reported a greater incremental increase in peak plasma glucose levels followed by an average of 20% greater insulin secretion in patients who ingested sucralose. Following ingestion of sucralose, an average of 7% decrease in insulin clearance and a 23% decrease in insulin sensitivity was noted compared to water. The authors did not detect any significant differences between the effects of sucralose or water on glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide or glucagon incremental AUC.

The authors concluded, "Our results indicate that this artificial sweetener is not inert -- it does have an effect." In regards to the clinical importance of their findings, Pepino said, "What these all mean for daily life scenarios is still unknown, but our findings are stressing the need for more studies…Whether these acute effects of sucralose will influence how our bodies handle sugar in the long term is something we need to know."

M. Y. Pepino, C. D. Tiemann, B. W. Patterson, B. M. Wice, S. Klein. Sucralose Affects Glycemic and Hormonal Responses to an Oral Glucose Load. Diabetes Care, 2013; DOI: 10.2337/dc12-2221 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 06 June, 2013 and appeared in  DietObesityIssue 680

Past five issues: Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 | Issue 742 | Diabetes Clinical Mastery Series Issue 201 | Humulin Insulin Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
Statin Adherence Linked to New Onset Diabetes Risk
Posted July 25, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
HbA1c Increases with Age
Posted August 01, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
Regression from Prediabetes to Normal Glucose Reduces CVD Risk
Posted July 25, 2014
Connection between Type 1 Diabetes and Ulcerative Colitis?
Posted August 01, 2014
Comparing Weekly Dulaglutide to Daily Liraglutide
Posted August 01, 2014
New Way to Regenerate Beta Cells in Type 1 Diabetes Patients
Posted August 08, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you recommend SGLT-2 drugs for type 1 diabetes?
CME/CE of the Week
Greet Van den Berghe, MD, PhD

Category: General Diabetes
Credits: 1.0
Search Articles On Diabetes In Control